MGX
Metagenomi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.10
−2.65%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- -$0.64
- Revenue estimate
- $2.6M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.73
- EPS estimate
- -$0.55
- Revenue actual
- -$257.0K
- Revenue estimate
- $3.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -6.1%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.00
- PT range
- $5.00 – $7.00
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.55 | -$0.73 | Miss -31.99% | -$257.0K |
| May 11, 2026 | -$0.60 | -$0.61 | Miss -1.67% | $1.2M |
| Mar 5, 2026 | -$0.61 | -$0.60 | Beat 0.98% | $3.9M |
| Nov 11, 2025 | -$0.60 | -$0.55 | Beat 8.33% | $8.7M |
| Aug 12, 2025 | -$0.68 | -$0.54 | Beat 20.59% | $8.5M |
| Mar 17, 2025 | -$0.62 | -$0.63 | Miss -1.61% | $9.6M |
| Nov 13, 2024 | -$0.70 | -$0.45 | Beat 35.71% | $11.5M |
| Aug 14, 2024 | -$0.59 | -$0.29 | Beat 50.85% | $20.0M |
| Feb 10, 2024 | -$2.04 | -$0.51 | Beat 74.76% | $12.4M |
| Jun 30, 2022 | — | -$1.57 | — | $3.3M |
| Mar 31, 2022 | — | -$1.57 | — | $3.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026